Clinical Trials on Prostate Adenocarcinoma Without Neuroendocrine Differentiation

Total 1348 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Neuroendocrine Prostate Cancer | Small Cell Prostate Cancer | Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
Dana-Farber Cancer Institute
Blue Earth Diagnostics, Inc

Not yet recruiting

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Metastatic Prostate Cancer | Advanced Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Puerto Rico
Case Comprehensive Cancer Center

Terminated

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

Adenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Andrew J. Armstrong, MD
Bristol-Myers Squibb

Recruiting

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Metastatic Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Dana-Farber Cancer Institute

Completed

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Prostate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Jagiellonian University
University Hospital in Krakow

Recruiting

Clinical Application of the J-PET Scanner Prototype (JPET2Clinic)

Prostatic Neoplasms | Prostatic Hyperplasia | Prostate Cancer | Neuroendocrine Tumors | Neuroendocrine Carcinoma | Prostate Cancer Metastatic

Poland
University of California, San Francisco

Completed

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

Stage IIB Prostate Cancer | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer | Neuroendocrine Prostate Cancer

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Switzerland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7

United States
Universitaire Ziekenhuizen KU Leuven
AZ Sint-Jan AV; General Hospital Groeninge; AZ Sint-Blasius Dendermonde

Recruiting

Prospective Prostate Cancer and Patient-reported Outcomes Registry (Prosquare)

Prostate Cancer | Adenocarcinoma of the Prostate | Locally Advanced Prostate Carcinoma | Locally Advanced Prostate Adenocarcinoma

Belgium
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
University of California, San Francisco

Approved for marketing

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma | Prostate

United States
University Hospital, Rouen

Recruiting

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies (OPALE)

Metastatic Prostate Adenocarcinoma

France
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7

United States
Aarhus University Hospital
Karolinska University Hospital; Karolinska Institutet; University of Aarhus; Central... and other collaborators

Unknown

Early and Accurate Detection of Prostate Cancer in General Practice

Prostate Cancer | Prostate Adenocarcinoma | Prostate Neoplasm

Denmark
Imperial College London
Wellcome Trust; Imperial Clinical Trials Unit (ICTU)

Completed

PROState Pathway Embedded Comparative Trial (IP3-PROSPECT)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate Cancer

United Kingdom
University of Wisconsin, Madison

Active, not recruiting

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD)

Prostate Adenocarcinoma | Metastatic Prostate Adenocarcinoma | Castration-resistant

United States, Brazil
Calibr, a division of Scripps Research

Terminated

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Adenocarcinoma

United States
Imperial College London
Prostate Cancer UK; Imperial Clinical Trials Unit (ICTU)

Recruiting

Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer (IP4-CHRONOS)

Prostate Cancer | Prostate Adenocarcinoma | Non-metastatic Prostate Cancer

United Kingdom
Virginia Commonwealth University

Terminated

Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer

United States
Crozer-Keystone Health System

Recruiting

CyberKnife Dose Escalation Prostate Cancer Trial (CK-DESPOT)

Prostate Cancer | Prostate Adenocarcinoma | Prostate Neoplasm

United States
Consorci Sanitari de Terrassa

Not yet recruiting

Prostatic Size Reduction Following of Leuprorelin Acetate (PROSTSIZE)

Prostate Adenocarcinoma | Prostate Cancer Adenocarcinoma

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Sir Mortimer B. Davis - Jewish General Hospital
Abbott

Recruiting

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Adenocarcinoma of the Prostate

Canada
Virginia Commonwealth University

Completed

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

Adenocarcinoma of the Prostate

United States
Dana-Farber Cancer Institute
Medivation, Inc.

Completed

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Prostate Cancer | Prostate Adenocarcinoma | High Risk Prostate Cancer

United States
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Completed

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Clinical Trials on Prostate Adenocarcinoma Without Neuroendocrine Differentiation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations